PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladie…
Author: Business Wire
GenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Ophthalmic Lens and Precision Optics Manufacturing Machines Global Strategic Business Report to 2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmic Lens and Precision Optics Manufacturing Machines – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Ophthalmic Lens and Precision Optics Manufac…
STAAR Surgical Experience Center Expands to Meet Growing Surgeon Demand
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, is proud to announce the e…
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) announces it has entered into a definitive asset purchase agreement (the “Agreement”) with PRN Physician Recommended Nutriceuticals, L…
Seeing a Clearer Path to Eye Health Equity: 20/20 Onsite Mobile Vision Clinic to Conduct Free Eye Screenings at the American Diabetes Association® DMV Step Out: Walk to Stop Diabetes® on 9/21/24
WASHINGTON–(BUSINESS WIRE)–20/20 Onsite Mobile Vision Clinic to Conduct Free Eye Screenings at the American Diabetes Association® DMV Step Out: Walk to Stop Diabetes®
RxCell Inc. Granted U.S. Patent for iPSC-based Cell Therapy
PARK CITY, Utah–(BUSINESS WIRE)–RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled “Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source”, a significant advancement in the field of regen…
Tough2gether Selects Bublup for Comprehensive Content Management and Community Forum
WASHINGTON–(BUSINESS WIRE)– #brainstormsummit–Tough2gether, an organization dedicated to the fight against pediatric brain tumors, has chosen Bublup, the all-in-one visual cloud platform, to manage content and facilitate community engagement. This c…
2024 Market Research | Significant Market Growth for TEPEZZA in the Treatment of Graves' Ophthalmopathy by 2032 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “TEPEZZA Market Size, Forecast, and Market Insight – 2032” report has been added to ResearchAndMarkets.com’s offering. This comprehensive analysis of the TEPEZZA market has highlighted a considerable growth forecast for the…
Eye Health Supplements Global Outlook & Forecasts 2024-2029 with Amway, Bausch Health Companies, Nature's Bounty, Vitabiotics, and ZeaVision Leading the $3.28 Billion Market – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eye Health Supplements Market – Global Outlook & Forecast 2024-2029” report has been added to ResearchAndMarkets.com’s offering. The Eye Health Supplements Market was valued at USD 2.22 billion in 2023, and is expected…
Ray Therapeutics Appoints Christopher Whitmore as Chief Financial Officer
SAN FRANCISCO–(BUSINESS WIRE)– #CFO–Ray Therapeutics Appoints Christopher Whitmore as Chief Financial Officer
Kopin Receives Second Production Order for Wearable Surgical Information Display
WESTBOROUGH, Mass.–(BUSINESS WIRE)–Kopin Corporation (NASDAQ: KOPN) a leading provider of application-specific optical solutions and high performance microdisplays for defense, enterprise, consumer and medical products, announced today that it has re…
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten p…
Morphotonics Announces First Closing of a $10+ Million Series B Funding Round
EINDHOVEN, Netherlands–(BUSINESS WIRE)–On its 10th anniversary, Morphotonics announces the launch of its Series B financing round, marking a significant endorsement of its mission to elevate global display technology. New investors 3M and BOM (Braban…
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwr…
Marshall B. Ketchum University Appoints Greta Vines-Douglas as New Director of Its School of Physician Assistant Studies
FULLERTON, Calif.–(BUSINESS WIRE)–Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution, is delighted to announce the appointment of Greta Vines-Douglas, MS, PA-C, as the new director of its Sc…
Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
ATLANTA–(BUSINESS WIRE)–Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, toda…
Inflammasome Therapeutics Completes Enrollment in Study for First Oral Dual Inflammasome Inhibitor for Ophthalmic and Neuroinflammatory Diseases
NEWTON, Mass.–(BUSINESS WIRE)– #ALS–Inflammasome Therapeutics, a private company, has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug K9, which has application in the treatment of multiple neuroinflammat…
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from t…
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to r…